Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: This study aimed to compare the current Essen rabies post-exposure immunization schedule (0-3-7-14-28) in China and the simple 4-dose schedule (0-3-7-14) newly recommended by the World Health Organization in terms of their safety, efficacy, and protection.

Methods: Mice were vaccinated according to different immunization schedules, and blood was collected for detection of rabies virus neutralizing antibodies (RVNAs) on days 14, 21, 28, 35, and 120 after the first immunization. Additionally, different groups of mice were injected with lethal doses of the CVS-11 virus on day 0, subjected to different rabies immunization schedules, and assessed for morbidity and death status. In a clinical trial, 185 rabies-exposed individuals were selected for post-exposure vaccination according to the Essen schedule, and blood was collected for RVNAs detection on days 28 and 42 after the first immunization.

Results: A statistically significant difference in RVNAs between mice in the Essen and 0-3-7-14 schedule groups was observed on the 35th day ( < 0.05). The groups 0-3-7-14, 0-3-7-21, and 0-3-7-28 showed no statistically significant difference ( > 0.05) in RVNAs levels at any time point. The post-exposure immune protective test showed that the survival rate of mice in the control group was 20%, whereas that in the immunization groups was 40%. In the clinical trial, the RVNAs positive conversion rates on days 28 (14 days after 4 doses) and 42 (14 days after 5 doses) were both 100%, and no significant difference in RVNAs levels was observed ( > 0.05).

Conclusion: The simple 4-dose schedule can produce sufficient RVNAs levels, with no significant effect of a delayed fourth vaccine dose (14-28 d) on the immunization potential.

Download full-text PDF

Source
http://dx.doi.org/10.3967/bes2024.018DOI Listing

Publication Analysis

Top Keywords

rvnas levels
12
simple 4-dose
8
4-dose schedule
8
immunization schedules
8
blood collected
8
clinical trial
8
statistically difference
8
difference rvnas
8
days doses
8
rvnas
7

Similar Publications

Article Synopsis
  • The study compared the current Essen rabies immunization schedule (0-3-7-14-28) in China with the newly recommended 4-dose schedule (0-3-7-14) by the WHO, focusing on their safety and efficacy.
  • Mice were used to measure the effectiveness of both schedules in generating rabies virus neutralizing antibodies (RVNAs), and a clinical trial with 185 individuals was conducted to evaluate real-world outcomes.
  • Results indicated that the 4-dose schedule effectively produced RVNAs with a 100% positive conversion rate in humans, and delaying the fourth dose did not significantly impact immune response.
View Article and Find Full Text PDF

A novel mRNA rabies vaccine as a promising candidate for rabies post-exposure prophylaxis protects animals from different rabies viruses.

Microb Pathog

December 2023

National Institute for Viral Disease Control and Prevention, China CDC, Key Laboratory of Biosafety, National Health Commission, Beijing, 102206, Beijing, People's Republic of China. Electronic address:

Article Synopsis
  • - Rabies, a deadly zoonotic disease caused by the rabies virus, leads to about 59,000 deaths yearly and poses significant public health challenges due to expensive vaccination procedures.
  • - Researchers evaluated SYS6008, an mRNA vaccine for rabies that showed promising results by inducing strong and lasting antibody responses in mice and cynomolgus macaques while offering better protection than standard vaccines.
  • - The study demonstrated SYS6008's effectiveness in both pre-exposure and post-exposure scenarios against multiple rabies virus clades, indicating its potential as a more accessible and affordable vaccine option.
View Article and Find Full Text PDF

Objective: Preliminary assessment of rabies virus neutralizing activity, safety and immunogenicity of a recombinant human rabies antibody (NM57) compared with human rabies immunoglobulin (HRIG) in Chinese healthy adults.

Methods: Subjects were randomly (1:1:1) allocated to Groups A (20 IU/kg NM57), B (40 IU/kg NM57), or C (20 IU/kg HRIG). One injection was given on the day of enrollment.

View Article and Find Full Text PDF

Background: SYN023-002 is a randomized, blinded, controlled study comparing rabies virus neutralizing activity (RVNA) and safety of SYN023, a monoclonal anti-rabies antibody mixture, to human-serum derived anti-rabies immunoglobulin (RIG) when administered with commercially available vaccines to healthy adult volunteers.

Methods: Participants were randomized among 4 treatment groups (SYN023 + Imovax, SYN023 + RabAvert, HyperRab + Imovax, HyperRab + RabAvert). On Day 0, subjects received 1 dose of RIG (0.

View Article and Find Full Text PDF

Alum adjuvanted rabies DNA vaccine confers 80% protection against lethal 50 LD rabies challenge virus standard strain.

Mol Immunol

May 2017

Laboratory of Molecular Biology and Genetic Engineering, School of Biotechnology, Jawaharlal Nehru University, New Delhi, 110067 Delhi, India. Electronic address:

Rabies is a serious concern world-wide. Despite availability of rabies vaccines for long; their efficacy, safety, availability and cost effectiveness has been a tremendous issue. This calls for improvement of rabies vaccination strategies.

View Article and Find Full Text PDF